lifestyle.thedishh.com

Author: Opus Genetics, Inc.

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

March 3, 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

February 27, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

February 25, 2026
Opus Genetics Announces $25 Million Private Placement

February 13, 2026
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

February 7, 2026
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

January 27, 2026